Ladenburg raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $24 from $21 and keeps a Buy rating on the shares following the Q3 report. The firm increased its probability of sucess in soquelitinib’s peripheral T-cell lymphoma indication to 80%, viewing the chemotherapy arm as a relatively easy comparator.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals price target raised to $14 from $8 at Oppenheimer
- Corvus Pharmaceuticals Reports Q3 2024 Financial Results
- Corvus Pharmaceuticals reports Q3 EPS (60c), consensus (11c)
- Corvus Pharmaceuticals options imply 17.7% move in share price post-earnings
- Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings
Questions or Comments about the article? Write to editor@tipranks.com